2013 Fiscal Year Final Research Report
Clinical trial of adjuvant peptide vaccine therapy for oral cancer研究代表者
| Project/Area Number |
23659953
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHITAKE Yoshiyasu 熊本大学, 医学部附属病院, 助教 (00423682)
HIRAKI Akimitsu 熊本大学, 大学院・生命科学研究部, 講師 (60404034)
NAKAYAMA Hideki 熊本大学, 大学院・生命科学研究部, 助教 (70381001)
|
|---|
| Project Period (FY) |
2012 – 2013
|
| Keywords | 口腔癌 / ペプチドワクチン / 腫瘍拒絶抗原 / 免疫療法 / アジュバンド療法 |
|---|
| Research Abstract |
Our cancer vaccination therapy using these peptides was welltolerated for oral cancer . 5 patients showed a postoperative local recurrence and metastasis(peritoneal dissemination;1 case, lung metastasis;1 case , cervical lymph node metastasis; 2cases and local recurrence; 1case). However , metastatic foci without peritoneal disseminationwere removed and all cases are continued vaccination therapy using these peptides. In all ofcases, recurrence and/or metastasis are not recognized after treatment.In the HLA-24(+) group, ELISPOT assay indicated that the URLC10-, CDCA1-, andKOC1-specific CTL responses were observed after the vaccination in 88.2%, 82.4%, and 52.9%,of the HLA-24(+) group, respectively. The patients showing URLC10 and CDCA1 specificCTL responses revealed the better clinical response, respectively. Conclusions: V accination using these peptides was well tolerated, and measurable immuneresponses and antitumor efficacy are observed. The immune response induced by thisvaccination can make their prognosis better for head and neck cancer patients
|
